What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Long-acting amylin analog
Vialdyne primary owner
This Vialdyne page is the primary SEO owner for buyers evaluating Cagrilintide through a pharmacy QA, clinic procurement, or regulated-sourcing workflow. It should answer whether the buyer can request a batch COA, release-test scope, destination-market review, and add-on documentation before moving into pricing or repeat inventory planning.
Overview
Cagrilintide (Novo Nordisk NN9838) is a 37-residue long-acting amylin analogue. The lipidation strategy mirrors the approach used on Semaglutide, an albumin-binding fatty-acid handle that pulls plasma half-life into a once-weekly dosing range, but the receptor pharmacology is entirely separate: this molecule engages the amylin receptor and the broader calcitonin-receptor family, both of which feed into satiety, gastric emptying, and energy balance through pathways anatomically distinct from GLP-1 signalling. The clinical centre of gravity for Cagrilintide is the CagriSema fixed combination with Semaglutide (Novo Nordisk's Phase 3 REDEFINE program), where the amylin-axis and GLP-1-axis effects layer rather than compete. For compounding pharmacy buyers, Vialdyne releases lyophilised Cagrilintide acetate against a ≥99.0% main-peak HPLC specification with a batch COA covering RP-HPLC, ESI-MS identity, Karl Fischer water, and counter-ion. Two procurement paths exist for CagriSema-style preparations: the standalone Cagrilintide vials, for pharmacies that prefer to control the blend ratio in their own cleanroom; or the pre-blended co-lyophilised CagriSema SKU, with the released ratio certified on the batch COA. The co-lyophilised path is the preferred default. Amylin-class peptides are known to be surface-active and to aggregate at solid-liquid interfaces when held in dilute aqueous solution, the co-lyophilised cake locks the ratio at the freeze-drying step and avoids the in-solution drift window that solution-phase mixing introduces.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for Cagrilintide, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →Cagrilintide
VD260428-CGL10042 · 98.92%
VerifiedRequest full COA →Cagrilintide
VD260428-CGL040 · 99.37%
VerifiedRequest full COA →Cagrilintide
VD260428-CGL5041 · 99.55%
Regulatory note
Still an investigational compound, catalogued by Novo Nordisk as NN9838, Cagrilintide has not yet been approved as a finished drug. We furnish it as a pharmaceutical-grade active intended for research and, where local rules allow, for compounding-pharmacy use. Its CagriSema combination is presently in Phase 3 development.
Selected literature
Frequently asked questions
Two separate signalling axes converge on the same clinical endpoint, but through different anatomy. Amylin acts at the area postrema and across the calcitonin-receptor family; GLP-1 acts at the arcuate-nucleus GLP-1R and peripheral targets. Because the inputs are parallel rather than redundant, layering the two produces additive effects on satiety, gastric-emptying rate, and weight reduction that neither monotherapy reaches at its own ceiling dose. The Phase 2 REDEFINE-2 readouts crystallised this, the dose-equivalent weight-reduction signal was materially larger than Semaglutide monotherapy and motivated the Phase 3 expansion.
It depends on where the blending step needs to live. Compounding pharmacies and 503B outsourcing facilities preparing a defined CagriSema dosage form are best served by the pre-blended co-lyophilised CagriSema SKU, the released-batch COA certifies the actual ratio in the vial (within tight tolerance) rather than just the theoretical ratio, which simplifies the QA-file evidence for a finished-product release. Standalone Cagrilintide vials make sense when the pharmacy or sponsor needs to vary the ratio between batches under its own quality system, or when bench-scale receptor-pharmacology work calls for ratio titration.
Amylin and its analogues are surface-active by nature, this is the same physical chemistry that drives native amylin to fibrillate in the pancreatic islet under disease conditions, and it carries over to the synthetic analogue. The lyophilised cake is stable across the standard 24-month re-test window at -20 C, but in-solution behaviour is the more sensitive part of the workflow. Reconstituted material should be used promptly, sub-divided into single-use aliquots immediately, and held in low-bind plasticware where possible; long-hold frozen working stocks should be avoided. Repeat freeze-thaw is the dominant cause of measured-potency loss, not slow temperature drift, so the operational rule is to minimise thaw cycles rather than to optimise freezer setpoint.
Related peptides
